Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2010

View Archived Issues

Omeros receives USD 25 million in funding for GPCR program

Data from several studies on mitoxantrone for relapsing-remitting MS made available

Merck & Co. identifies new renin inhibitors

Clinical trials explore efficacy of budesonide in treating eosinophilic esophagitis

Effects of denosumab reported in patients with prostate cancer and bone metastases

AstraZeneca and Daiichi Sankyo announce agreement to copromote Nexium in Japan

Results reported from second phase III study of aclidinium bromide in COPD

FDA requests additional information from VIVUS regarding Qnexa NDA

Cellceutix completes final toxicity study of Kevetrin

Emergent BioSolutions acquires Trubion Pharmaceuticals

Neuron BioPharma describes new antioxidants/HMG-CoA reductase inhibitors

Third quarter highlights at Abbott

Teva Pharma to acquire Theramex, a women's health business, from Merck Serono

Acadia enters agreement with Biovail to regain rights to pimavanserin

Shire reports data from phase II Vyvanse study in major depressive disorder

Mild toxicity and disease stabilizations seen with L19TNF-alpha in patients with cancer

Merck Serono presents new lysophospholipid S1P1 receptor agonists

New inhibitors of Ras-related C3 botulinum toxin substrate 1 claimed

GSK and Amicus to develop Amigal for Fabry's disease

StemCells begins second clinical trial of HuCNS-SC in Batten disease

FDA approves Avanir's Nuedexta for treatment of pseudobulbar affect

Inhibitex begins phase Ib trial of INX-189 in chronic HCV infections

Spectrum Pharma submits additional data to FDA for Fusilev

FDA approves Afinitor as first treatment for benign brain tumor associated with tuberous sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...